acyclovir / Generic mfg. - LARVOL DELTA

Dara-RVD in newly diagnosed multiple myeloma: Real-world clinical practice (ASH 2025) - "Depending on post-ASCT MRD status, patients received lenalidomide maintenance therapy, if MRD negativity was achieved...Antitumor treatment was administered alongside supportive therapy (sulfamethoxazole-trimethoprim, acyclovir), immunoglobulin infusions, osteomodifying agents...Seven patients underwent stem cell harvesting (etoposide 750 mg/m 2 )combined with short-acting filgrastim without routine plerixafor administration...Conclusion : In the context of limited access to CAR T-cell and bispecific therapies in Russia, early use of Dara-RVd with MRD-adaptive strategies shows high efficacy, including high-risk NDMM patients. This quadruplet-based approach may shift the treatment paradigm, though careful monitoring for complications like hypogammaglobulinemia is essential."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Musculoskeletal Pain • Pneumococcal Infections • Renal Disease • Respiratory Diseases • CD34 • CTCs

Risk factors for varicella zoster virus reactivation in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation (ASH 2025) - "Maintenance therapy consisted of lenalidomide in 53 (56%) patients, bortezomib for two years in 14 (15%) patients, thalidomide in 4 (4%) patients and other combination for the other 29 patients...Regarding VZV reactivation severity, 85% were grade 2, treated with oral aciclovir or valaciclovir, 2 (10%) grade 3 and one patient (5%) grade 4...This study is the first to describe, in a real-world cohort of MM patients undergoing ASCT, the prevalence and potential risk factors for VZV reactivation also in vaccinated patients. The possible role of prognostic biomarkers, namely B2M levels, in predicting VZV reactivation needs to be confirmed in larger datasets."

Clinical • IO biomarker • CNS Disorders • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Leukemia • Multiple Myeloma • Plasma Cell Leukemia • Renal Disease • Transplantation • Varicella Zoster • B2M • CD4

HSV-1 infection as a rare trigger of methotrexate toxicity: A diagnostic and therapeutic challenge (ASH 2025) - "Four days earlier, she was seen in an outpatient clinic for a cold sore near the corner of her right lip and was prescribed valacyclovir 500 mg twice daily for three days for HSV infection. Her home medications included prednisone 2.5 mg, leucovorin 5 mg and methotrexate 12.5 mg weekly along with adalimumab 40 mg every 14 days...Intravenous hydrocortisone 50 mg twice daily was initiated...After a five-day course of IV steroids and a seven-day course of IV cefepime, she was discharged home on oral acyclovir to complete a 14-day total antiviral course... This case suggests that corticosteroids may be a valuable adjunct in patients with suspected methotrexate toxicity who do not respond to leucovorin. Further studies are needed to evaluate the role of corticosteroids in such cases."

Cardiovascular • Congestive Heart Failure • Diabetes • Endocrine Disorders • Febrile Neutropenia • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Herpes Simplex • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Neutropenia • Renal Disease • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis • Thrombocytopenia • Type 2 Diabetes Mellitus

Real world treatment outcome with azacytidine (AZA)-tocilizumab (TCZ) for reducing steroid dependence in vexas syndrome with myelodysplastic syndrome (MDS): A single-center, 1.5-year longitudinal observational study (ASH 2025) - "Treatment and outcome: The patient was initiated on high-dose prednisone (PRD) at 40 mg daily and Erythropoiesis-Stimulating Agent, leading to clinical improvement...Acyclovir, atovaquone and voriconazole were used for anti-microbial prophylaxis... As VEXAS syndrome is a novel disease, there is absence of standardized treatment guidelines. This case highlights the promise of AZA-TCZ combination therapy in steroid dependent VEXAS syndrome with MDS. Further investigation into targeted steroid-sparing regimens along with patient specific guidelines is warranted for durable disease control and improved outcomes."

Clinical • HEOR • Observational data • Real-world • Real-world evidence • Eosinophilia • Hematological Disorders • Hematological Malignancies • Inflammation • Leukopenia • Musculoskeletal Diseases • Myelodysplastic Syndrome • Neutropenia • Ocular Inflammation • Ophthalmology • Orthopedics • Renal Disease • Retinal Vein Occlusion • Uveitis

Daratumumab for immune-mediated thrombotic thrombocytopenic purpura (iTTP): Results from the international, multicenter darttp study (ASH 2025) - "Patients had received a median of 3 (IQR 2)previous IST, including rituximab (100%), bortezomib and mycophenolate (25% each), cyclosporine andcyclophosphamide (20% each), azathioprine (15%), vincristine (10%), obinutuzumab, ofatumumab, andsplenectomy (5% each). Seventeen patients received daratumumab in the remission phase (i.e., forADAMTS13 relapse or intolerance to other IST), while 3 during an acute episode (plasma-based therapyand caplacizumab ongoing in 3 and 2 patients, respectively)...Disease duration, previous IST used, daratumumab schedule, ordemographics did not correlate with response or its duration...A patient not receiving acyclovir had a grade 2 zoster skininfection 3 months after her last daratumumab infusion. in this study, daratumumab warranted rapid ADAMTS13 remission in 75% of iTTP patientsrefractory or intolerant to rituximab and other conventional IST... in this study, daratumumab warranted rapid ADAMTS13 remission in 75% of iTTP patientsrefractory..."

Clinical • Cardiovascular • Dermatology • Hematological Disorders • Herpes Zoster • Thrombocytopenic Purpura • CD20

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study (ASH 2025) - "Prophylactic valacyclovir is routinely administered toprevent varicella-zoster virus (VZV) infection...All cases presented with localized pain and rash without systemic symptoms, and weremanaged with oral acyclovir. No cases of disseminated or severe VZV infection were observed.ConclusionTwo doses of RZV seems to induce humoral responses in the vast majority of patients with monoclonalgammopathies, with minimal toxicity. A minority of patients on anti-myeloma treatment withbreakthrough VZV infections had adequate IgG antibody levels, no systemic symptoms, and weresuccessfully managed with oral antiviral therapy."

Clinical • CNS Disorders • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Infectious Disease • Keratitis • Lymphoma • Lymphoplasmacytic Lymphoma • Monoclonal Gammopathy • Multiple Myeloma • Neuralgia • Ocular Inflammation • Ophthalmology • Varicella Zoster • Waldenstrom Macroglobulinemia • XPO1

Immune reconstitution and infectious complications following CAR-T cell therapy (ASH 2025) - "Anti infectious prophylaxis was given as follows: anti-filamentous antifungals duringneutropenic periods, acyclovir and anti-Pneumocystis jirovecii (PJP) until CD4+cell count >200 cells/µL...No HSV-1/2, fungal, or PJPinfections were observed.Regarding risk factors for infections, steroid therapy for >10 days (p=0,001), the administration of >1 doseof tocilizumab (p=0,041) and the occurrence of grade ≥2 cytokine release syndrome (CRS) (p=0,036), wereassociated with increased infectious burden (one grade ≥3 or more than 3 Grade ≥2 infections)... In this real-world series we confirm that CAR-T cell recipients have prolonged immunedysfunction and infection risk, well beyond the first year after therapy. Prolonged steroid use wasassociated with increased risk of severe and/or repeated infections. Further immune characterization inlarger patient cohorts is needed to further identify risk factors for infections in these patients."

CAR T-Cell Therapy • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • CD4

Efficacy and safety of RCD pulse regimen for acquired Hemophilia A (ASH 2025) - "TheRCD pulse regimen is a combined immunosuppressive therapy (IST) consisting of: 500mgcyclophosphamide intravenously on days 1, 8, 15, and 22; 40mg dexamethasone, intravenously or orally,on days 1, 8, 15, and 22; and 100mg rituximab intravenously on days 1, 8, 15, and 22...All patients received infection prophylaxis with sulfamethoxazole and trimethoprim (480 mgonce daily) and acyclovir (400 mg once daily)...Two patientswith inhibitors > 100 BU and 2 patients with inhibitors < 20 BU did not achieve CR after prednisolonealone or combination therapy with the addition of cyclophosphamide prior to RCD.To date, 7 of the 8 (87.5%) patients have achieved CR after 1 or 2 courses of RCD (3 newly diagnosedpatients after 1 courses of RCD, 1 newly diagnosed patient and 3 relapsed patients after 2 courses ofRCD). One patient who relapsed after 313 weeks of treatment with prednisone and other drugs cannotbe treated strictly in accordance with the protocol of this study, and has..."

Clinical • Breast Cancer • Cataract • CNS Disorders • Coronary Artery Disease • Depression • Diabetes • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • Heart Failure • Hemophilia • Hemophilia A • Hypertension • Immunology • Infectious Disease • Interstitial Lung Disease • Metabolic Disorders • Nephrology • Ophthalmology • Pneumonia • Psychiatry • Rare Diseases • Renal Disease • Respiratory Diseases • Rheumatology • Solid Tumor

PSD04 Recurrent and persistent genital ulcers in an immunocompromised man: an uncommon presentation of herpes zoster. (PubMed, Br J Dermatol) - "He is currently on an oral daily dose of tenofovir 300 mg, lamivudine 300 mg, dolutegravir 50 mg, atazanavir 300 mg and ritonavir 100 mg...Complete resolution was obtained with a higher dose of aciclovir appropriate for VZV infection...This case was interesting because VZV as an aetiological agent for persistent genital ulcers has not previously been reported to the best of our knowledge. Clinical consideration of such a unique presentation of VZV is important for timely diagnosis and appropriate management, especially in immunocompromised individuals, to avoid possible complication of repeated treatment for HSV infection."

Journal • Cytomegalovirus Infection • Herpes Simplex • Herpes Zoster • Human Immunodeficiency Virus • Infectious Disease • Pain • Varicella Zoster • CD4

PA23 A case of neonatal scabies. (PubMed, Br J Dermatol) - "However, subsequent HSV polymerase chain reaction was negative and aciclovir was therefore ceased. Empirical treatment with flucloxacillin and gentamycin was also stopped due to no evidence of ongoing infection...Here we present an immunocompromised neonate who was successfully treated with permethrin 5%. Skin lesions can include erythematous papules, nodules and crusts, and in the absence of positive skin scrapings a careful history and examination of close contacts should lead to the eventual diagnosis."

Journal • Atopic Dermatitis • Critical care • Dermatology • Hepatology • Herpes Simplex • Immunology • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Septic Shock

Recurrence of acyclovir-resistant herpes encephalitis in an immunocompromised patient: A case report. (PubMed, World J Clin Cases) - "ARHE recurred in the patient following remission; therefore, it is necessary to discuss the length of the treatment period."

Journal • CNS Disorders • Hematological Disorders • Herpes Simplex • Infectious Disease • Movement Disorders

Desensitization to Acyclovir: A Case Report. (PubMed, J Investig Allergol Clin Immunol) - No abstract available

Journal • Allergy • Immunology

An Atypical Presentation of Enteroviral Meningitis in an Immunocompetent Adult Man. (PubMed, Cureus) - "The patient was started empirically on intravenous (IV) ceftriaxone, vancomycin, and acyclovir. This case underscores that early LP and comprehensive diagnostic evaluation are essential when clinical findings are nonspecific. Maintaining a broad differential and relying on clinical judgment rather than physical signs alone can help prevent missed or delayed diagnoses."

Journal • Cardiovascular • CNS Disorders • Hypertension • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain

Disseminated herpes simplex virus type 1 treated with ixekizumab in a patient with erythrodermic psoriasis: A case report. (PubMed, World J Clin Cases) - "This case highlights the diagnostic and therapeutic challenges of managing EP in the setting of biologic therapy. Disseminated cutaneous HSV-1 should be considered in immunosuppressed patients presenting with new vesicular eruptions, and prompt PCR testing with early antiviral therapy is essential. A multidisciplinary approach is critical to balance immunosuppression for disease control with infection risk."

Journal • Bipolar Disorder • CNS Disorders • Critical care • Dermatology • Dermatopathology • Eosinophilia • Fibrosis • Gastroenterology • Hematological Disorders • Hepatology • Herpes Simplex • Immunology • Infectious Disease • Liver Cirrhosis • Mood Disorders • Psoriasis • Psychiatry

Rhoifolin prevents herpes simplex virus encephalitis by modulating SESN2 to regulate the Keap1/Nrf2 and AMPK/Nox pathways to inhibit neuro-oxidative damage in mice. (PubMed, Phytomedicine) - "ROF treatment successfully saved lethal HSE mice by curbing viral replication and oxidative stress, leading to improved neural damage and reduced neuroinflammation. The underlying mechanism involves enhancing the expression of SESN2 in various types of neural cells and regulating the downstream Keap1/Nrf2 and AMPK/Nox pathways."

Journal • Preclinical • CNS Disorders • Herpes Simplex • Infectious Disease • Inflammation • SESN2

Unveiling the molecular mechanism of acyclovir interaction with carbon dots: a DFT approach. (PubMed, J Mol Model) - "3.08) software, utilizing the wave function from the M06-2X method with a 6-31 G** basis set. NBO 7.0 was used to conduct natural bond orbital (NBO) analysis, while the Chemcraft package and VMD were employed for visualizations."

Journal

Zinc Oxide-Polyvinyl Alcohol Nanocomposite: A Promising Antiviral Agent against Acyclovir-Sensitive and Resistant Herpes Simplex Virus Type 1. (PubMed, Microb Pathog) - "The ZnO-PVA nanocomposite exhibited significant antiviral effects against both acyclovir-sensitive and acyclovir-resistant HSV-1, suggesting its potential as an effective therapeutic agent."

Journal • Herpes Simplex • Infectious Disease

Evaluating antibiotic medications delivered through elastomeric devices in a paediatric population: a systematic review. (PubMed, Arch Dis Child) - "EDs have been used for a range of antimicrobial agents in children, in the treatment of a variety of infections, mostly in CF patients, and few adverse events were reported. Further studies should concentrate on new patient groups, and specific information about safety and cost effectiveness of ED in children is required."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases

PRIOH-1: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (clinicaltrials.gov) - P3 | N=158 | Completed | Sponsor: AiCuris Anti-infective Cures AG | Active, not recruiting ➔ Completed

Trial completion • Herpes Simplex • Infectious Disease

An Immunocompetent Host With Severe Disseminated Herpes Simplex Virus Type 2 Infection With Hepatorenal Involvement. (PubMed, Cureus) - "The patient was treated with intravenous acyclovir followed by oral valacyclovir, resulting in complete resolution of symptoms and normalization of liver and renal function. Given ongoing high-risk sexual behavior, he was also counseled on long-acting injectable HIV pre-exposure prophylaxis with lenacapavir...Early recognition and prompt antiviral therapy are critical to improving clinical outcomes. Physicians should consider a high index of suspicion for HSV hepatitis in candidates presenting with unexplained transaminitis and systemic symptoms, even in the absence of classic mucocutaneous findings or immunosuppression."

Journal • Acute Kidney Injury • Hepatology • Herpes Simplex • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Failure • Nephrology • Oncology • Renal Disease

Phenobarbital for Refractory Behavioral Disturbances in Anti-NMDAR and HSV Encephalitis: A Case Report. (PubMed, J Pain Palliat Care Pharmacother) - "Disease-modifying therapies, including IV acyclovir, IV immunoglobulin, prednisone, and rituximab, were ineffective. Multiple psychotropic medications, including fluoxetine, quetiapine, olanzapine, and trazodone, failed to relieve behavioral symptoms...No adverse effects were reported. This case suggests that low-dose oral phenobarbital may be a viable option for managing refractory behavioral disturbances in patients and improving quality of life with anti-NMDAR and HSV encephalitis."

Journal • CNS Disorders • Herpes Simplex • Immunology • Insomnia • Mental Retardation • Palliative care • Psychiatry • Sleep Disorder

Primary Genital HSV-2 Infection in a Resource-Limited Setting: Diagnostic Challenges and Clinical Implications. (PubMed, Cureus) - "Treatment with oral acyclovir, cefadroxil, and mefenamic acid, supplemented by topical gentamicin and counselling on recurrence risk and safe sexual practices, led to complete lesion resolution within 14 days and no recurrence at six-week follow-up. These limitations hinder accurate case identification and contribute to the underrecognition of HSV-2 prevalence. Early clinical recognition, prompt antiviral initiation, and strengthened patient education remain essential for mitigating morbidity, preventing recurrence, and reducing transmission in low-resource environments."

Journal • Herpes Simplex • Human Immunodeficiency Virus • Infectious Disease • Pain

Acute confusional migraine in adults – A case report (EHF-EHC 2025) - "Diazepam, haloperidol, and chlorpromazine were administered, but agitation persisted...Lumbar puncture was performed, and empiric antibiotics plus acyclovir were started but discontinued within hours after normal CSF and negative viral PCR...Although self-limiting, no abortive treatment is available; however, valproic acid and topiramate may be used to treat and prevent recurrences. The absence of formal criteria and the diagnosis being one of exclusion hinder clinical recognition."

Case report • Clinical • Cardiovascular • CNS Disorders • Hypertension • Migraine • Pain

Case report: Atypical trigeminal herpes zoster in a migraineur: Diagnostic and therapeutic challenges (EHF-EHC 2025) - "A diagnosis of herpes zoster was established, and intravenous acyclovir was initiated... Although a direct link between migraine and herpes zoster remains unproven, immune imbalance in migraine patients may predispose them to atypical infections. Therefore, herpes zoster should be included in the differential diagnosis when managing refractory or atypical headache presentations. Keywords: migraine, herpes zoster"

Case report • Clinical • CNS Disorders • Herpes Zoster • Infectious Disease • Migraine • Ophthalmology • Pain • Varicella Zoster

SUNCT-like headache secondary to herpes zoster in the ipsilateral ophthalmic nerve distribution: A case report (EHF-EHC 2025) - "A 52-year-old Sri Lankan male developed painful vesicular eruptions over the right ophthalmic dermatome and was treated with oral acyclovir (800 mg, five times daily)...Treatment included oral prednisolone (15 mg/day, tapered by 5 mg/week), carbamazepine (100 mg t.d.s., increased to 200 mg t.d.s. from week two), pregabalin (75 mg nocte), and tramadol (50 mg nocte)...This case underscores a SUNCT-like syndrome following ophthalmic zoster, which appears more pharmacoresponsive than primary SUNCT. Immunosuppressive states like diabetes, should be considered underlying zoster reactivation."

Case report • Clinical • Diabetes • Herpes Zoster • Metabolic Disorders • Ophthalmology • Pain • Varicella Zoster